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BACKGROUND: Despite the best standard treatment, optimal cytoreductive surgery (CRS) and platinum/taxane-
based chemotherapy, prognosis of advanced epithelial ovarian carcinoma (EOC) remains poor. Recently, CRS plus
hyperthermic intraperitoneal chemotherapy (HIPEC) has been developed to treat peritoneal carcinomatosis (PC).
This study was to evaluate the efficacy and safety of CRS+HIPEC to treat PC from advanced/recurrent EOC.
METHODS: Forty-six PC patients from advanced EOC (group A) or recurrent EOC (group B) were treated by 50
CRS+HIPEC procedures. The primary endpoints were progression-free survival (PFS) and overall survival (OS); the
secondary endpoints were safety profiles. RESULTS: The median OS was 74.0 months [95% confidence interval
(CI) 8.5-139.5] for group A versus 57.5 months (95% CI 29.8-85.2) for group B (P = .68). The median PFS was not
reached for group A versus 8.5 months (95% CI 0-17.5) for group B (P = .034). Better median OS correlated with
peritoneal cancer index (PCI) b 20 (76.6 months for PCI ≤ 20 group vs 38.5 months for PCI N 20 group, P = .01),
complete cyroreduction (residual disease ≤ 2.5 mm) [79.5 months for completeness of cytoreduction (CC) score
0-1 vs 24.3 months for CC 2-3, P = .00], and sensitivity to platinum (65.3 months for platinum-sensitive group vs
20.0 for platinum-resistant group, P = .05). Serious adverse events occurred in five patients (10.0%). Multivariate
analysis identified CC score as the only independent factor for better survival. CONCLUSION: For advanced/
recurrent EOC, CRS+HIPEC could improve OS with acceptable safety.
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Epithelial ovarian cancer (EOC) causes more deaths than any other
malignancy affecting the female reproductive system. In up to 75% of
the patients, the disease is diagnosed at an advanced stage, with
peritoneal involvement or distant metastasis [International Federation
of Gynecology and Obstetrics (FIGO) stage III to IV], and for such
patients. the overall 5-year survival rate is less than 20% [1].
The standard treatment of advanced EOC is based on optimal
cytoreductive surgery (CRS) to remove all the visible tumors if
possible, followed commonly by intravenous platinum/taxane-based
chemotherapy [2,3]. However, even after the best standard treatment,
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70% of advanced EOC patients experience a relapse, mostly in the
form of peritoneal carcinomatosis (PC) [4]. There has been no
curative treatment for EOC PC. Repeated conventional chemother-
apy alone or in combination with molecular targeting agents could
improve survival and quality of life at the cost of considerable
treatment-related adverse events [5,6].
Over the past three decades, aggressive CRS plus hyperthermic
intraperitoneal chemotherapy (HIPEC) has been developed as a
comprehensive treatment package integrating multivisceral resections to
remove the macroscopic tumor and HIPEC to eradicate the microscopic
residual disease. In China, we have conducted a series of preclinical and
clinical studies on the feasibility, efficacy, and safety of this multidisci-
plinary treatment approach in animal models [7] and in clinical setting
[8,9]. The benefits of this treatment package have been demonstrated in
PC patients from gastric cancer [9,10], colorectal cancer [11],
pseudomyxoma peritonei, and peritoneal mesothelioma. As a result, a
regional PC center has been set up, and a prospective database has been
established. In this report, we summarized our experience in 50
CRS+HIPEC procedures for the treatment of 46 EOC patients.
Patients and Methods
Patient Selection
This is a retrospective cohort study on prospectively established
database covering 46 consecutive Chinese patients with advanced
EOC (FIGO stage IIIc/IV, n = 16, group A) or recurrent EOC with
PC (n = 30, group B), aged from 22 to 75 years old (median 57.5
years), treated by 50 CRS+HIPEC procedures from March 2005 to
September 2014. Among the 30 patients in the recurrent group were
25 patients at the first recurrence, 3 patients at the second recurrence,
and 2 patients at the third recurrence. The inclusion criteria were 1)
age 20 to 75 years; 2) Karnofsky performance status N 50; 3)
peripheral blood white blood cells count ≥ 3500/mm3 and platelet
count ≥80,000/mm3; 4) acceptable liver function, with bilirubin
≤ 2× the upper limit of normal (ULN) and aspartic aminotransferase
and alanine aminotransferase ≤ 2× ULN; 5) acceptable renal
function, with serum creatinine ≤ 1.5 mg/dl; and 6) cardiovascular
pulmonary and other major organ functions could stand major
operation. Major exclusion criteria were 1) age b 20 years or N 75
years; 2) any lung metastasis, liver metastasis, or prominent
retroperitoneal lymph node metastasis during preoperative assess-
ment; 3) serum bilirubin level N 3× ULN; 4) liver enzymes N 3×
ULN; and 5) serum creatinine level N 1.5 mg/dl. Informed consent
was obtained from all patients, and the study was approved by the
institutional review board and the ethics committee.
CRS plus HIPEC Procedure
All CRS+HIPEC procedures were conducted by a designated team
focusing on PC treatment. In brief, the abdominal exploration was
performed through a midline xiphoid-pubic incision after general
anesthesia, and peritoneal cancer index (PCI) was evaluated and
recorded according to Sugarbaker's criteria [12]. Then maximal CRS
was performed. The extent of CRS was determined by Sugarbaker's
criteria [13] on the completeness of cytoreduction (CC). A score of
CC 0 indicates no residual peritoneal disease after CRS; CC 1, less
than 2.5 mm of residual disease; CC 2, residual tumor between
2.5 mm and 2.5 cm; and CC 3, more than 2.5 cm of residual tumor
or the presence of a sheet of unresectable tumor nodules.After CRS, open HIPEC was implemented with cisplatin 100 mg/m2
andmitomycinC (MMC)20mg/m2 in 35 cases, andpaclitaxel 100mg/m2
and lobaplatin 50 mg/m2 in 15 cases with increased risk of renal
dysfunctions, each dissolved in 6 l of heated saline at temperature of 43.0 ±
0.5°C. The total HIPEC time was 60minutes, after which gastrointestinal
anastomoses or stomata were made. After operation, the patient was
delivered to the intensive care unit for recovery. When the condition
stabilized, the patients were transferred to the surgical oncology ward.
Postoperative Chemotherapy
Postoperative adjuvant chemotherapy was delivered within 2 to 3
weeks after CRS+HIPEC, including platinum/taxane-based systemic
chemotherapy (SC) and perioperative intraperitoneal chemotherapy
(PIC) through the intraperitoneal chemotherapy port once every 3 to
4 weeks mainly using cisplatin 100 mg/m2 and paclitaxel 100 mg/m2.
For platinum-resistant disease, paclitaxel 100mg/m2 and doxorubicin 35
mg/m2 were used. The median cycles of postoperative adjuvant
chemotherapy (SC and/or PIC) were 6 (range, 0-26), and the median
cycles of postoperative PIC were 3 (range, 0-9).
Study Endpoints and Definition
The primary endpoints of this study were progression-free survival
(PFS) calculated from the date of CRS+HIPEC to the date of disease
progression and the overall survival (OS) defined as the time interval
from the first treatment to death due to the disease. Patients with
recurrent EOC were further divided into platinum-sensitive or
-resistant subgroups according to the established criteria [14]. The
secondary endpoints were the perioperative serious adverse events
(SAEs), defined as complications directly attributable to the treatment
within 30 days of CRS+HIPEC, based on theNational Cancer Institute
Common Terminology Criteria for Adverse Events version 4.0 [15].
Follow-Up
All patients were regularly followed up once every 3 months for the
first 2 years and every 6 months thereafter for detailed information on
disease status. Patients alive at the time of analysis were censored at
the last follow-up. The follow-up package included physical
examination, serum tumor markers (CA125, CEA, and CA19-9),
and imaging examination, with the most recent follow-up on
February 28, 2015. No patient was lost to follow-up.
Statistical Analysis
The patient information was systematically integrated into a
prospectively established database. Data analysis was conducted using
the Statistical Package for Social Sciences version 17.0 (SPSS, Inc.,
Chicago, IL). The numerical data were directly recorded, and the
category data were recorded into different categories. The Kaplan-
Meier method was used to compare the survival with log-rank test,
and multivariate Cox regression analysis was performed to delineate
the independent predictors. Subgroup OS comparisons were
performed by HIPEC timing (primary versus recurrent), PCI [low
PCI (LPCI) versus high PCI (HPCI)] (PCI ≤ 20 defined as LPCI, and
PCI N 20 defined as HPCI), and CC score (CC 0-1 vs CC 2-3). A
two-sided P b .05 was considered as statistically significant.
Results
Major Clinical and Pathological Characteristics of the Patients
A total of 46 patients with stage IIIc/IV EOC (n = 16) and
recurrent EOC (n = 30) were treated with 50 CRS+HIPEC
Table 2. Intraoperative Parameters of the 46 EOC PC Patients
Items Value, n (%)
PCI
Median PCI (range) 20 (7-39)
≤20 24 (52.2)
N20 22 (47.8)
CC scores
0-1 28 (60.9)
2-3 18 (39.1)
Surgical procedures; organ resection
Resection of jejunum 1 (0.2)
Resection of ileum 7 (15.0)
Right colectomy 17 (26.1)
Transverse colectomy 4 (8.7)
Descending colectomy 3 (6.5)
Sigmoidectomy 6 (13.0)
Rectectomy 9 (19.6)
Splenectomy 4 (8.7)
Resection of ovarian/fallopian tube 16 (34.8)
Hysterectomy 7 (15.0)
Partial hepatectomy 1 (0.2)
Cholecystectomy 4 (8.7)
Appendectomy 7 (15.0)
Partial gastrectomy 1 (0.2)
Number of organ resected
0 resection 15 (32.6)
1-3 resections 24 (52.2)
4-8 resections 7 (15.0)
Peritonectomy
Greater/lesser/omentum 46 (100.0)
Left diaphragmatic copula 5 (10.9)
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procedures due to tumor recurrence. The detailed clinical and
pathological characteristics were listed in Table 1, and the major
intraoperative parameters and surgical procedures were listed in Table 2.
Survival of the Total Population
By February 28, 2015, the median follow-up time was 45.8 months
(range, 5.0-213.3), and 24 patients (52.1%) were deceased and 22
patients (47.8%) were still alive. The median OS was 57.5 months
[95% confidence interval (CI) 23.2-91.7], and the 1-, 3-, 5-year survival
rates were 97.8%, 65.2% and 56.5%, respectively (Figure 1).
Subgroup analysis was conducted. For group A of 16 patients with
advanced EOC, the median PFS was not reached; for group B of 30
patients with recurrent EOC, the median PFS was 8.5 months (95%
CI 0-17.5) (P = .034, log-rank test).
The median OS was 74.0 months (95% CI 8.5-139.5) in group A
versus 57.5 months (95% CI 29.8-85.2) in group B (P = .68, log-rank
test) (Figure 2A). The median OS for patients with LPCI (n = 24)
versus HPCI (n = 22) was 76.6 months (95% CI 56.5-96.7) versus
38.5 months (95% CI 24.2-52.8) (P = .01, log-rank test) (Figure 2B).
The median OS for patients with CC 0 to 1 versus CC 2 to 3 was
79.5 months (95% CI, 64.8-94.2) versus 24.3 months (95% CI
13.9-34.7) (P = .00, log-rank test) (Figure 2C). For recurrent patients,
the median OS was 65.3 months (95% CI 42.6-88.9) for
platinum-sensitive patients versus 20.0 months (95% CITable 1. Major Clinicopathologic Characteristics of the 46 Patients
Items Value, n (%)
Median age (years) 58
b60 25 (54.3)
≥60 21 (45.7)
Median Karnofsky performance score (range) 70 (50-90)
HIPEC timing
Primary (IIIc/IV) 16 (34.8)
Recurrent 30 (65.2)
Histopathology
Serous adenocarcinoma 34 (73.9)
Mucinous adenocarcinoma 11 (23.9)
Endometrioid carcinoma 1 (2.2)
Histopathology differentiation
Well differentiated 11 (23.9)
Intermediately/poorly differentiated 35 (76.1)
Comorbidity
Yes 18 (39.1)
No 28 (60.9)
Neoadjuvant chemotherapy for primary EOC PC
Yes 5 (31.2)
No 11 (68.8)
SAE
Yes 5 (10.0)
No 45 (90.0)
Median postoperative chemotherapy cycles † 6
b6 17 (37.0)
≥6 29 (63.0)
Median postoperative intraperitoneal chemotherapy cycles † 3
Median postoperative hospital stay (days) (range) * 11 (4-43)
Median ICU stay (hours) (range) * 15 (0-89)
Median gastric tube removal time (days) (range) * 5 (2-13)
Platinum sensitivity for recurrent patients (n = 30)
Sensitive 16 (53.3)
Nonsensitive 14 (46.7)
* A total of 50 CRS+HIPEC procedures were performed for 46 patients, including 4 patients each having
2 procedures.
† According to the first CRS+HIPEC procedure.
Right diaphragmatic copula 23 (50.0)
Right colon gutter 22 (47.8)
Left colon gutter 17 (37.0)
Liver round ligament/sickle ligament 46 (100.0)
Douglas pouch 23 (50.0)
Anterior wall peritoneum 12 (26.1)
Pelvic peritoneum 34 (73.9)
Mesenteric fulguration 33 (71.7)
Peritoneal regions resected
1-3 regions 17 (37.0)
4-6 regions 15 (32.6)
7-10 regions 14 (30.4)
Number of anastomosis
None or stoma only 30 (65.2)
=1 12 (26.1)
N1 4 (8.7)
Fluid output volume at surgery (median, range) (ml)
Blood loss 600 (100-2000)
Urine output 1000 (100-3350)
Ascites 1000 (0-4500)
≤1000 25 (54.3)
N1000 21 (45.7)
Fluid intake volume at surgery (median, range)
Plasma (ml) 450 (0-1550)
Red blood cells (U) * 3 (0-16)
Cryoprecipitation (U) † 4 (0-14)
Other fluids (ml) 4000 (2000-8000)
CRS+HIPEC duration (median, range) (h) 7.5 (4.5-13.5)
* 1 U = 200 ml.
† 1 U = 25 ml.14.5-23.5) for platinum-resistant patients (P = .05, log-rank test)
(Figure 2D).
Special Analysis on Patients with OS over 60 Months
By the last follow-up, there were 9 patients (19.6%) with OS over
60 months (Table 3). Four patients had no evidence of tumor
recurrence, with OS of 70.0, 72.5, 75.5, and 122.7 months,
respectively. One patient was alive with tumor recurrence, living over
Figure 1. The Kaplan-Meier overall survival curve of the whole patients in this study. mo, months.
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tumor recurrence, with a median OS of 75.5 months (range,
65.3-204.0).
DetailedDescription of Four Patients with Repeated CRS+HIPEC
There were four patients that each had two CRS+HIPEC
treatments in this study including one primary advanced and three
recurrent EOC patients. Two patients survived more than 5 years,
and one patient was still alive without tumor with OS of 122.7
months. She reached CC 0 resection in two CRS+HIPEC procedure.
The other 2 patients had OS of 38.4 and 38.5 months, respectively.
The detailed information was listed in Table 4.
SAE Analysis
There was no 30-day perioperative death in this study. SAEs
occurred in five patients, including small intestinal leakage in one
patient, ascending colon leakage in one patient, protracted
postoperative intestinal obstruction in one patient, wound infection
with Escherichia coli sepsis in one patient, and pseudomembranous
colitis in one patient. The detailed clinical course of these five patients
was listed in Table 5.
A binary logistic regression analysis was conducted to study the
correlation of SAEs with major treatment parameters. There were no
significant correlations between SAEs and age, FIGO stage,
histopathology, organ and peritoneal resection area, PCI score, and
CC score.
Tumor Recurrent after CRS+HIPEC
At the time of last follow-up, tumor recurrence was documented in
35 cases, and most patients experienced tumor recurrence in morethan 1 site (Table 6). In terms of frequency, 26 (56.5%) patients had
peritoneal recurrence including abdominopelvic mass, intestinal
obstruction, and malignant ascites; 9 (19.6%) patients had lymphatic
metastasis; 6 (13.0%) patients had hematogenous metastasis
including liver, spleen, lung, and bone metastasis; and 6 (13.0%)
patients had malignant pleural effusion.
Univariate and Multivariate Analysis on Predictors of OS
A univariate analysis identified 3 covariates indicative of improved
survival, including CC 0 to 1, PCI ≤ 20, and ascites ≤ 1000 ml.
Multivariate Cox regression analysis identified CC scores as the only
independent predictors for better survival. Compared with CC 2 to 3,
CC 0 to 1 was about 7 times (hazard ratio = 7.2, 95% CI 1.9-27.0,
P b .01) more likely to improve survival (Table 7).
Discussion
In this study, we performed 50 CRS+HIPEC procedures as a
comprehensive treatment strategy on 46 patients with advanced or
recurrent EOC, achieving 1-, 3- and 5-year survival rates of 97.8%,
65.2%, and 56.5%, respectively. Of special note are the nine patients
with OS N 5 years, including four patients still disease free at the time
of the most recent follow-up. Special analysis of these patients reveals
several features. First, these patients were relatively young at the time
of treatment. Among the 9 cases, there were 8 patients ≤ 65 years old
and only 1 patient aged 67 years. Second, these patients had relatively
low PCI at the time of surgery. Among the 9 cases, there were 8
patients with PCI b 20 and only 1 patient with PCI 22. Third, these
patients were mostly platinum-sensitive cases. Among the nine cases,
eight patients were presumably platinum sensitive and 1 patient
platinum resistant. Fourth, most patients had extensive CRS to
Figure 2. The Kaplan-Meier overall survival curve by treatment time from first treatment (A), by PCI (B) and by CC score (C) for both primary
and recurrent EOC patients, and by platinum sensitivity (D) for recurrent EOC patients.
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CRS+HIPEC treatment.
As stage IIIc/IV and recurrent EOC are not curable by the current
standard treatment of conventional surgery and taxane- and
platinum-based SC [3], even with the recent addition of molecular
targeting agents [16,17], many surgical and gynecological oncologists
have performed more extensive CRS to minimize tumor burden and
HIPEC to eradicate microscopic residual tumors and free cancer cells
after operation [18–23]. This comprehensive treatment package
integrates surgery, chemotherapy, and tumor heating and washing in
one treatment setting, different from any other previously applied
therapies that separate surgical therapy or medical therapy as
independent treatments.
There have been several published studies on CRS+HIPEC to treat
advanced EOC [24–26]. These studies achieved median OS of 28.5
to 77.8 months and 5-year survival rates of 28.0% to 72.0%. A
multicenter phase II trial from Italy [24] to study upfrontCRS+HIPEC for advanced EOC achieved a median PFS of 30.0
months and 5-year OS and PFS rates of 60.7% and 15.2%,
respectively. Gonzalez et al. [26] studied the different time points of
CRS+HIPEC to treat advanced EOC, and the median OS was 77.8
months for patients treated upfront, 62.8 months at first recurrence,
and 35.7 months at second or subsequent recurrence. In our study,
the 5-year survival rate for advanced EOC is similar to that reported
in the literature.
Many studies also used CRS+HIPEC to treat recurrent EOC
[23,27,28], achieving median OS of 37.0 to 48.9 months and 5-year
survival rates of 35% to 41.3%. Our median OS was relatively higher
than others, reaching 57.5 months (95% CI 29.8-85.2) in the
recurrent group. Due to the heterogeneity of patient selection and
complexity of this therapy strategy, most published reports were phase
I [29] and phase II [30] studies, but the most recent phase III
prospective randomized trial by Spiliotis et al. [18] on 120 patients
with recurrent EOC has provided more convincing evidence. In this
Table 3. Major Clinicopathological Features of 9 Patients with OS N 60 Months
No. Age
(Years)
P/R Histopathology CRS * HIPEC PCI CC OS/PFS
(Months)
Comments
1 43 P Serous-mucinous
cystadenocarcinoma,
moderately differentiated
Resection of pelvic peritoneum,
anterior wall peritoneum, hysterectomy
and resection of bilateral ovarian/fallopian
tube, mesenteric fulguration
DDP 100 mg/m2,
MMC 20 mg/m2
15 0 70.0/
70.0,
DFS
Comorbidity: poliomyelitis
sequel period, polycystic liver,
and polycystic kidney
2 62 P Serous papillary
adenocarcinoma,
moderately
differentiated
Right diaphragmatic copula peritoneum,
left/right paracolic sulci peritoneum,
pelvic peritoneum, liver round ligament
resection, hysterectomy and resection of
ovarian/fallopian tube
DDP 100 mg/m2,
MMC 20 mg/m2
19 1 74.5/
16.5,
SWT
Pleurectomy and
hyperthermic intrathoracic
chemotherapy were
conducted 2 years after
CRS+HIPEC due to
pleural metastasis
3 32 P Mucinous
cystadenocarcinoma,
well differentiated
Resection of bilateral ovarian/fallopian tube,
pelvic peritoneum, and liver round ligament
DDP 100 mg/m2,
MMC 20 mg/m2
15 0 72.5/
72.5,
DFS
4 49 R Serous papillary
adenocarcinoma,
moderately-poorly
differentiated
Sigmoidectomy, rectectomy, resection of
pelvic peritoneum
DDP 100 mg/m2,
MMC 20 mg/m2
11 1 75.5/
72.5,
DFS
5 57 R Borderline serous
cystadenocarcinoma,
moderately
differentiated
Resection of right paracolic sulci peritoneum,
pelvic peritoneum, anterior wall peritoneum
DDP 100 mg/m2,
MMC 20 mg/m2
16 0 76.6/
18.0, D
6 50 R Serous papillary
adenocarcinoma,
moderately-poorly
differentiated
1st: ileectomy, resection of anterior wall peritoneum
2nd: resection of pelvic peritoneum, anterior wall
peritoneum and bilateral fossa iliaca peritoneum,
mesenteric fulguration
1st: DDP 100 mg/m2,
MMC 20 mg/m2,
2nd: Lobaplatin 50 mg/m2,
TAX 100 mg/m2
1st: 20
2nd: 22
1st: 1
2nd: 2
65.3/
8.5, D
Intraperitoneal extensive
bowel adhesions were found
at the second operation
7 67 R Endometrioid
carcinoma, poorly
differentiated
Resection of right paracolic sulci peritoneum,
right diaphragmatic copula peritoneum, pelvic
peritoneum, anterior wall peritoneum
DDP 100 mg/m2,
MMC 20 mg/m2
16 1 204.0/
54.0,D
A total of 4 operations and 2
TACEs were implemented
from first treatment to death
8 51 R Borderline mucinous
cystadenocarcinoma,
moderately differentiated
Resection of left/right diaphragmatic
copula peritoneum, left/right paracolic
sulci, pelvic peritoneum and bilateral
fossa iliaca peritoneum
DDP 100 mg/m2,
MMC 20 mg/m2
22 1 79.5/
16.0, D
SAE: small intestinal leakage,
abdominal infection (Proteus
mirabilis infection)
9 60 R Mucinous
cystadenocarcinoma,
moderately differentiated
1st: greater/lesser omentectomy, appendicectomy
2nd: resection of ileocecum, left/right diaphragmatic
copula peritoneum and ascending colon
1st: DDP 100 mg/m2,
MMC 20 mg/m2,
2nd: Lobaplatin 50 mg/m2,
TAX 100 mg/m2
1st: 5
2nd: 8
1st: 0
2nd: 0
122.7/
58.0,DFS
Comorbidity: hypertension;
type 2 diabetes mellitus
P, primary; R, recurrent; DDP, cis-platinum; TAX, paclitaxel; TACE, transcatheter arterial chemoembolization; DFS, disease-free survival; SWT, survival with tumor; D, died.
PFS was calculated from the first CRS+HIPEC in this table.
* Greater omentectomy and lesser omentectomy were performed on all the nine patients.
Table 4. Major Clinicopathological Features on 4 Patients Undergoing Twice CRS+HIPEC Procedures
No. Age
(Years)
P/R Histopathology CRS HIPEC PCI CC OS/PFS
(Months)
Comments
1 50 R Serous papillary
adenocarcinoma,
moderately-poorly
differentiated
1st: ileectomy, resection of anterior wall peritoneum;
2nd: resection of pelvic peritoneum, anterior wall
peritoneum and bilateral fossa iliaca peritoneum,
mesenteric fulguration
1st: DDP 100 mg/m2,
MMC 20 mg/m2,
2nd: lobaplatin 50 mg/m2,
TAX 100 mg/m2
1st: 20,
2nd: 22
1st: 1,
2nd: 2
OS: 65.3,
PFS 1: 8.5,
PFS 2: 6.0, D
Intraperitoneal
extensive bowel
adhesions were
found at the
second operation
2 60 R Mucinous
cystadenocarcinoma,
moderately
differentiated
1st: greater/lesser omentectomy, appendicectomy
2nd: resection of ileocecum, left/right diaphragmatic
copula peritoneum and ascending colon
1st: DDP 100 mg/m2,
MMC 20 mg/m2,
2nd: lobaplatin 50 mg/m2,
TAX 100 mg/m2
1st: 5,
2nd: 8
1st: 0, 2nd: 0 OS: 122.7,
PFS 1: 58.0,
PFS 2: 19.6,
DFS
Comorbidity:
hypertension; type 2
diabetes mellitus
3 61 P Serous papillary
adenocarcinoma,
moderately-poorly
differentiated
1st: right hemicolectomy, splenectomy, cholecystectomy,
hysterectomy and resection of bilateral
ovarian/fallopian tube. Greater/lesser omentectomy,
resection of right diaphragmatic copula peritoneum,
right/left paracolic sulci peritoneum, pelvic peritoneum,
mesenteric fulguration
2nd: partial gastrectomy, resection of anterior wall peritoneum,
bilateral fossa iliaca peritoneum, mesenteric fulguration
1st: lobaplatin 50 mg/m2,
TAX 100 mg/m2
2nd: lobaplatin 50 mg/m2,
TAX 100 mg/m2
1st: 22,
2nd: 23
1st: 1, 2nd: 2 OS: 38.4,
PFS 1: 14.0,
PFS 2: 5.1,
SWT
4 69 R Serous adenocarcinoma,
poorly differentiated
1st: transverse colectomy, resection of right/left diaphragmatic
copula peritoneum, right/left paracolic sulci peritoneum, pelvic
peritoneum, mesenteric fulguration
2nd: proctosigmoidectomy, resection of bilateral fossa iliaca
peritoneum, mesenteric fulguration
1st: DDP 100 mg/m2,
MMC 20 mg/m2,
2nd: lobaplatin 50 mg/m2,
TAX 100 mg/m2
1st: 15,
2nd: 23
1st: 1, 2nd: 2 OS: 38.5,
PFS 1:10.0,
PFS 2:8.0, D
Grade 4
myelosuppression
during postoperative
chemotherapy;
comorbidity:
hypertension;
coronary heart
disease
PFS 1, from the first CRS+HIPEC to disease progression; PFS 2, from the second CRS+HIPEC to disease progression.
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Table 5. Detailed Data on 5 Patients with SAE *
No. Age
(Years)
P/R Histopathology CRS HIPEC PCI CC SAE Treatment OS
(Months)
1 67 R Serous papillary
adenocarcinoma,
moderately differentiated
Greater omentectomy, mesenteric fulguration DDP 100 mg/m2,
MMC 20 mg/m2
39 3 Ascending colon leakage
(POD 8), abdominal MRSA
infection (POD 12)
CT 32.3, D
2 51 R Borderline mucinous
cystadenocarcinoma,
moderately
differentiated
Resection of left/right diaphragmatic copula
peritoneum, left/right paracolic sulci, pelvic
peritoneum and bilateral fossa iliaca peritoneum
DDP 100 mg/m2,
MMC 20 mg/m2
22 1 Small intestinal leakage
(POD 6), abdominal
infection (Proteus mirabilis
infection, POD 15)
CT 79.5, D
3 56 R Serous
cystadenocarcinoma,
poorly differentiated
Left hemicolectomy, left lower quadrant abdominal
giant tumor resection, resection of part left upper
quadrant of the abdomen peritoneum and round
ligament of liver, mesenteric fulguration
Lobaplatin 50 mg/m2,
TAX 100 mg/m2
19 1 Tumor recurrence,
abdominal giant lump,
intestinal obstruction (POD 14)
CT 32.9, D
4 55 R Serous papillary
adenocarcinoma,
moderately
differentiated
Greater omentectomy, ileectomy, sigmoid colon
and rectum resection, peritonectomy of the pelvis,
right and left paracolic gutter, round ligament of
liver resection
Lobaplatin 50 mg/m2,
TAX 100 mg/m2
33 3 Infection of incisional wound
with Escherichia coli sepsis
(POD 14)
CT 16.3, D
5 44 R Serous papillary
cystadenocarcinoma,
poorly differentiated
Greater/lesser omentectomy, splenectomy, cholecystectomy,
right hemicolectomy, sigmoidectomy, rectectomy, right
diaphragmatic copula, anterior wall and pelvic peritonectomy
Lobaplatin 50 mg/m2,
TAX 100 mg/m2,
43 °C, 60 min
33 2 Pseudomembranous colitis
(POD 14)
CT 6.2, D
POD, postoperative days; CT, conservative treatment; MRSA, methicillin-resistant Staphylococcus aureus.
* Common Terminology Criteria for Adverse Events version 4.0.
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group versus CRS alone group (P b .01). Three-year survival rate
was 75% for CRS+HIPEC group versus 18 % for CRS alone group
(P b .01).
One of the most important factors to determine the success of
CRS+HIPEC is the PCI to reflect the degree of PC. In our study, the
median PCI was 20, with 24 patients (52.2%) having PCI ≤ 20 and
22 patients (47.8%) having PCI N 20. We found that patients with
PCI ≤ 20 had median OS of 76.6 months, whereas those with
PCI N 20 had median OS of only 38.5 months (P = .01). At the same
time, univariate analysis identified PCI ≤ 20 as an independent factor
for better survival. So far, there has been no clear dividing line to
determine the degree of PCI, although most reports used PCI 10
[23], 12 [31], and 15 [32–34] as the dividing line. All these studies
indicated that patients with limited peritoneal cancer (relatively
LPCI) could benefit more from this comprehensive treatment,
emphasizing the importance of patient selection.
Complete CRS is another important factor for long-term survival.
In our study, patients with CC 0 to 1 CRS had median OS of 79.5
months, whereas those with CC 2 to 3 had median OS of only 24.3
months. Multivariate Cox regression analysis also identified CC score
as an independent factor for better survival. Compared with CC 2 to
3, CC 0 to 1 is about 7 times (hazard ratio = 7.2, 95% CI 1.9-27.0,
P b .01) more likely to improve survival. These findings are in
accordance with the literature reports [20,28]. Of special note is theTable 6. The Sites of Recurrence following HIPEC for the 46 Patients
Item N (%)
Peritoneal recurrence (including abdominopelvic mass,
intestinal obstruction, malignant ascites)
26 (56.5%)
Hematogenous (including liver, spleen, lung, bone metastasis) 6 (13.0)
Lymphatic metastasis 9 (19.6)
Malignant pleural effusion 6 (13.0)
Malignant ascites only 10 (21.7)
The second primary tumor 1 (2.1)
Intestinal obstruction 6 (13.0)exhaustive meta-analysis by Bristow et al. [35] on 81 clinical studies
totaling 6995 EOC patients treated during the platinum era, which
demonstrated that for every 10% increase in the rate of optimal CRS,
there is a 3-month OS increase for patients with recurrent EOC.
Therefore, every attempt should be tried to achieve maximal CRS.
However, extensive surgery means high potential morbidity and
mortality. In our experience, no perioperative death occurred, but five
patients developed SAE, including two with intestinal fistula, two
with severe infection and sepsis, and one patient with intestinal
obstruction. Although binary logistic regression analysis revealed no
significant correlations between SAEs and the clinical and operation
variables, several factors deserve special attention: First, these five
patients with SAE were all recurrent EOC; three were platinum
sensitive and two were platinum resistant. Second, these patients had
high PCI, 4 with PCI over 22 and only 1 with PCI 19. Third, these
patients had high CC score, 3 with CC 2 to 3 and 2 with CC 1; there
was no CC 0 patient. Fourth, SAE had significant detrimental impact
on survival. Therefore, intensive perioperative risk factors manage-
ment is warranted.
Conclusion
In summary, this retrospective cohort study on a prospectively
established database from China has provided evidence that
CRS+HIPEC could bring OS benefits calculated from first treatment
for advanced and recurrent EOC. More high-level evidence-based
clinical studies are needed to validate this strategy.
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Table 7. Univariate and Multivariate Analysis of Independent Factors Influencing OS
Covariate Univariate Analysis Multivariate Analysis
χ2 P HR 95% CI χ2 P HR 95% CI
CC score (CC 0-1 vs CC 2-3) 17.399 .000 7.937 3.003-12.277 8.743 .003 7.246 1.949-27.027
PCI (≤20 vsN 20) 5.998 .014 2.941 1.241-6.993 0.005 .943 1.045 0.316-3.455
Ascites (≤1000 ml vsN 1000 ml) 3.841 .050 2.398 1.000-5.747 1.341 .247 1.686 0.696-4.082
Age (≥60 vsb 60) 0.726 .394 1.436 0.625-3.301
Differentiated (well vs moderate/poorly) 1.517 .218 2.000 0.664-6.024
Comorbidity (yes vs no) 1.203 .273 1.616 0.685-3.809
HIPEC timing (primary vs recurrent) 0.170 .680 1.220 0.475-3.135
NACT (yes vs no) 0.535 .465 1.456 0.532-3.984
PIC (yes vs no) 0.422 .516 1.315 0.575-3.006
SAE (yes vs no) 1.114 .291 1.610 0.664-3.906
NACT, neoadjuvant chemotherapy.
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